Valganciclovir

Generic Name
Valganciclovir
Brand Names
Valcyte
Drug Type
Small Molecule
Chemical Formula
C14H22N6O5
CAS Number
175865-60-8
Unique Ingredient Identifier
GCU97FKN3R
Background

Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.

Indication

Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections.

Associated Conditions
Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis
Associated Therapies
-
Clinical Trials
Related News

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

First Posted Date
2007-04-27
Last Posted Date
2015-08-26
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
109
Registration Number
NCT00466817
Locations
🇺🇸

SUNY Upstate Medical University Hospital - Pediatrics, Syracuse, New York, United States

🇺🇸

Los Angeles County - University of Southern California - Medical Center - Pediatrics, Los Angeles, California, United States

🇺🇸

Plaza Towers Obstetrics and Gynecology, Los Angeles, California, United States

and more 45 locations

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

First Posted Date
2006-10-13
Last Posted Date
2019-08-02
Lead Sponsor
University of California, San Diego
Registration Number
NCT00387530
Locations
🇺🇸

Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States

TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant

Phase 2
Completed
Conditions
Cytomegalovirus Infection
First Posted Date
2006-10-11
Last Posted Date
2009-09-18
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
132
Registration Number
NCT00386412
Locations
🇪🇸

Hospital Clínico y Provincial de Barcelona, Barcelona, Spain

🇪🇸

Hospital Universitario "Germans Trias i Pujol", Barcelona, Spain

🇪🇸

Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain

and more 5 locations

Study of Prophylactic Vs Preemptive Valganciclovir

Not Applicable
Completed
Conditions
Cytomegalovirus Infection
First Posted Date
2006-09-11
Last Posted Date
2006-09-11
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
120
Registration Number
NCT00374686
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease

Phase 4
Withdrawn
Conditions
Giant Lymph Node Hyperplasia
Interventions
Drug: Valganciclovir
First Posted Date
2006-08-09
Last Posted Date
2017-04-18
Lead Sponsor
University of Washington
Registration Number
NCT00361933

Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)

First Posted Date
2006-05-25
Last Posted Date
2015-04-21
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
40
Registration Number
NCT00330018
Locations
🇮🇱

Hadassah Medical Organization,, Jerusalem, Israel

IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients

Phase 3
Completed
Conditions
Cytomegalovirus Infections
Interventions
Drug: Valganciclovir
First Posted Date
2006-02-22
Last Posted Date
2018-03-29
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
326
Registration Number
NCT00294515
Locations
🇺🇸

UCLA Medical Center, Los Angeles, California, United States

🇺🇸

Robert Wood Johnson Uni Hospital; Anesthesia, New Brunswick, New Jersey, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 77 locations

The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.

Phase 3
Completed
Conditions
Bone Marrow Stem Cell Transplant
First Posted Date
2006-01-12
Last Posted Date
2011-12-19
Lead Sponsor
Mayo Clinic
Target Recruit Count
20
Registration Number
NCT00275665
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients

Phase 3
Terminated
Conditions
Kidney Transplant
First Posted Date
2006-01-11
Last Posted Date
2015-12-17
Lead Sponsor
University of Pittsburgh
Target Recruit Count
5
Registration Number
NCT00275314
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Valganciclovir to Reduce T Cell Activation in HIV Infection

First Posted Date
2005-12-12
Last Posted Date
2020-07-31
Lead Sponsor
University of California, San Francisco
Target Recruit Count
30
Registration Number
NCT00264290
Locations
🇺🇸

San Francisco General Hospital - General Clinical Research Center, San Francisco, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy